ArticleCell reports. Medicine2022

Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma.

Anais Hagege et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.